Related Experiment Video

Updated: Oct 7, 2025

Author Spotlight: Purifying High-Quality Tubulin to Study Protein Dynamics and Therapeutic Applications
06:30

Author Spotlight: Purifying High-Quality Tubulin to Study Protein Dynamics and Therapeutic Applications

Published on: October 11, 2024

2.1K

Recent Advances in Combretastatin A-4 Inspired Inhibitors of Tubulin Polymerization: An Update

Sultan Nacak Baytas1

  • 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06330, Ankara, Turkey.

Current Medicinal Chemistry
|January 6, 2022
PubMed

Insights

Researchers are developing new cancer treatments by modifying Combretastatin A-4 (CA-4) to create novel microtubule-targeting agents (MTAs). These efforts focus on enhancing anticancer therapy through structural modifications of CA-4 analogues.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Cancer remains a leading global cause of death, driving research into novel therapeutic strategies.
  • Microtubules are critical for cell division and represent a promising target for anticancer drugs.
  • Combretastatin A-4 (CA-4) is a natural compound that inhibits microtubule polymerization by binding to the colchicine site.

Purpose of the Study:

  • To review recent advancements in the development of Combretastatin A-4 (CA-4) analogues.
  • To explore modifications of the CA-4 pharmacophore for improved anticancer activity.
  • To summarize new molecule development efforts reported since 2015.

Main Methods:

  • Literature review of scientific articles published since 2015.
  • Analysis of pharmacophore group modifications in Combretastatin A-4 analogues.
  • Synthesis and evaluation of novel microtubule-targeting agents (MTAs).

Main Results:

  • Numerous CA-4 analogues have been synthesized due to CA-4's simple structure.
  • Pharmacophore modifications have led to the development of new potential anticancer agents.
  • Recent research focuses on optimizing CA-4 derivatives for enhanced efficacy.

Conclusions:

  • The development of Combretastatin A-4 analogues represents a significant area of research in anticancer drug discovery.
  • Structural modifications of CA-4 continue to yield promising new microtubule-targeting agents.
  • Ongoing efforts aim to translate these findings into effective cancer therapies.
Keywords:
Combretastatin A-4MTAscancerdrug developmentmicrotubulestubulin polymerization inhibitors

More Related Videos

Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins08:13

Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins

Published on: November 30, 2021

2.6K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.8K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K